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ABSTRACT
Background: Video-assisted thoracic surgery (VATS) lo-
bectomy provides a minimally invasive alternative for
management of early stage non-small cell lung cancer, but
is still only performed in a few specialized centers around
the world. Questions about the safety of the surgery and
its adequacy as a cancer operation remain hurdles for
many surgeons.
Methods: We performed a systematic review of the liter-
ature on VATS lobectomy to assess these questions. The
MEDLINE database was queried and the papers analyzed.
Results: Four randomized control trials, 11 case-control
series, and 10 case series were reviewed. A variety of
VATS techniques are used, making generalization of re-
sults difficult. The weight of this evidence suggests that
VATS lobectomy can be safely performed and is an ade-
quate cancer operation for early stage non-small cell lung
cancer. There is also evidence that patients experience
less pain with VATS, but that length of hospital stay is
similar.
Conclusion: In expert hands, VATS lobectomy appears
to be a safe procedure. However, the published evidence
is thin and ongoing study is required, preferably with
standardization of VATS techniques.
Key Words: VATS, Lobectomy, Minimally invasive sur-
gery, Lung cancer.
INTRODUCTION
The earliest reports of minimally invasive lobectomies
were published more than a decade ago.1,2 Although
video-assisted thoracic surgery (VATS) has become the
method of choice for many procedures formerly done via
thoracotomy, the use of VATS for major lung resections
has lagged substantially behind. The reasons are mani-
fold. Performing anatomic lung resections by VATS is
more complex than the relatively simple open operation
and may require the use of special instruments. The in-
traoperative costs are higher. Perhaps most importantly,
because lung cancer is the most common indication for
performing lobectomy, the question of adequacy of the
operation in satisfying surgical oncologic principles re-
mains a hurdle in many surgeons’ minds. The main con-
siderations, therefore, in assessing whether to perform a
minimally invasive lobectomy are adequacy as a cancer
operation (as manifested by equivalent survival), safety in
terms of complications and mortality, relative cost (includ-
ing intraoperative and length of stay considerations), and
benefits for the patients in terms of decreased pain and
improved quality of life.
The definition of a VATS major lung resection can be
problematic, or at least vague. In the literature, VATS
lobectomy is a term used to describe a spectrum of oper-
ations from a mini-thoracotomy with rib-spreading and
direct visualization through the wound to a completely
minimally invasive approach with no rib-spreading and
use of only thoracoscopic instruments. In interpreting
studies of VATS lobectomy, careful review of the Methods
section usually sheds light as to the nature of the opera-
tion performed. This needs to be taken into account when
evaluating the evidence and forming conclusions.
METHODS
A systematic review of the literature was performed by
accessing the MEDLINE database from 1966 through June
2005. The subject heading search terms “carcinoma, non-
small-cell lung,” “lung non small cell cancer,” “lung ade-
nocarcinoma,” “lung alveolus cell carcinoma,” “lung squa-
mous cell carcinoma,” “surgery,” “cancer surgery,” “lung
surgery,” “thoracic surgery, video-assisted,” and “pneumo-
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SCIENTIFIC PAPERnectomy” were combined with the following phrases used
as text words: “non small cell lung,” “lobectomy,” “pneu-
monectomy,” “VATS,” “surgery,” “thoracoscopy,” “thora-
coscopic,” and “minimally invasive.” These terms were
then combined with the search terms for the following
publication types and study designs: practice guidelines,
systematic reviews, metaanalyses, randomized control tri-
als (RCTs), phase III clinical trials, and major clinical
studies.
Relevant articles (published in English) and abstracts were
selected and reviewed by the authors, and the reference
lists from those sources were searched for additional trials.
Studies were divided into the following groups: RCTs,
case-control studies, and case series. Patient consent and
Internal Review Board approval were not required.
RESULTS
The literature published to date on VATS lobectomy or
major lung resections is scant and largely of a lesser
weight on the evidence scale. A few authors from various
centers around the world are responsible for a large share
of the studies, and the majority of the data is in the form
of case series.
Randomized Control Trials
Few randomized control trials exist in this area (Table
1).3–6 Of the 3 published trials comparing open to VATS
lobectomies, 2 examine clinical outcomes and 1 investi-
gates biochemical markers.3–5 The first and most well-
known RCT was published by Kirby and colleagues.3
They randomized 61 patients with clinical stage I non-
small cell lung cancer (NSCLC) to undergo lobectomy by
VATS (31 patients) or muscle-sparing thoracotomy (30
patients). The VATS were performed without rib-spread-
ing. One patient in the open group and 2 patients in the
VATS group had benign disease and were excluded from
analysis. In addition, 3 patients in the VATS group re-
quired conversion to thoracotomy and were also excluded
from the analysis leaving 30 in the open and 25 in the
VATS groups. There were few differences between the
groups. The incidence of postoperative complications was
less in the VATS group (6% versus 16%). There were no
significant differences in operating time, blood loss, du-
ration of chest tube placement, length of hospital stay, and
incidence of disabling postthoracotomy pain (2 in the
open versus 1 in the VATS group).
The other RCT comparing clinical outcomes between
open and VATS lobectomy was published by a Japanese
group.4 Sugi and colleagues4 randomized 100 patients
with clinical stage IA lung cancer to open (52 patients) or
VATS (48 patients) lobectomy and mediastinal lymph
node dissection. The additional 2 patients in the open
group were conversions from VATS and were analyzed in
the open group. There were no significant differences in
the recurrence rates or survival. The reported 3- and
5-year survivals were 93% and 85% in the open group and
90% and 90% in the VATS group, respectively. Of note,
this is the only RCT to examine survival differences be-
tween VATS and open lobectomies.
A study comparing acute phase responses randomized 22
patients to VATS and 19 patients to open lobectomy.5
They used a nonrib-spreading technique, and all patients
had mediastinoscopy preoperatively. Blood samples were
taken before and at various times in the first week after
surgery. Both operations increased acute phase response
Table 1.
Randomized Control Trials of VATS Major Lung Resections
Study Patients Outcomes Results Comment
Kirby
3 1995 25 VATS
30 Open
LOS, OR time,
Complications
Less complications
in VATS, no other
differences
Stage I tumors, 3
VATS excluded
due to conversion
Sugi
4 2000 48 VATS
52 Open
Survival,
recurrences
No differences All pts had MLND
Craig
5 2001 22 VATS
19 Open
Acute phase
reactants
Lower CRP and
IL-6 in VATS
Shigemura
6 2004 18 Complete VATS
16 Assisted VATS
OR time, LOS,
pain,
complications,
markers
Longer OR,
Shorter LOS, lower
CRP with
complete
Complete VATS—
no spreading
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C-reactive protein (CRP) and interleukin (IL)-6.
A final RCT was performed comparing complete VATS
(c-VATS) to assisted VATS (a-VATS).6 The authors ran-
domized patients with clinical stage I lung cancer to either
a nonrib-spreading approach (c-VATS, 18 patients) or a
mini-thoracotomy approach with rib-spreading (a-VATS,
16 patients). The authors found significantly shorter
length of stay (11 versus 15 days), longer OR times, less
blood loss, and lower serum markers (CRP, white blood
cells) in the c-VATS group.
Case-Control Studies
A number of case-control studies examining a variety of
outcomes have been performed on VATS major lung
resections (Table 2).8–14,25–27 Two studies investigating
the effects of VATS lobectomies in high-risk patients
have been performed.7,8 A Japanese case-control study
done with patients 80 or older with 17 VATS cases and 15
open controls showed no significant difference in survival or
complications with trends favoring the VATS group.7
Demmy8 performed a case-control study comparing VATS
lobectomy patients with matched controls who had open
surgery. VATS was only offered to patients who were
deemed high risk based on either poor pulmonary function
tests (PFTs) or poor function. There were 19 patients in each
group. Despite having higher risk patients, the VATS group
had a shorter length of stay, a quicker return to activity,
and less pain 3 weeks postoperatively than did the open
group.
A number of other case-control series examining pain,
changes in PFTs, nocturnal hypoxemia, and various mark-
ers of inflammation have been performed and are sum-
marized in Table 2.10–14 They generally favored VATS
approaches, but the selection of controls was problematic.
For example, in one study of cytokines before and after
Table 2.
Case-Control Series of VATS Major Lung Resections
Study Patients Outcomes Results Comment
Shiraishi
25 2006 10 VATS
9 mini
19 Open
Mediastinal LNs, LOS,
pain by visual analog
scale
Equal Mediastinal LN
resected, Less pain in
VATS
Clinical Stage IA, pain less in
VATS vs. Open on POD 2
Watanabe
27 2005 191 VATS
159 Open
Number of mediastinal
LNs, mortality,
recurrence
Mediastinal LNs equal, 5
year recurrence free
survival similar
Groups not equivalent, more
T2 in open
Muraoka
26 2006 43 VATS
42 Open
Surgical invasiveness
parameters,
complications
Less blood loss, shorter
chest tube duration, less
pain, lower WBC and CRP
all in VATS
An overall decreased
morbidity rate in VATS (25.6%
vs. 47.6%), Clinical stage I
Demmy
8 1999 19 VATS
19 Open
LOS, Return to activity,
pain
All favor VATS High risk pts, 3 deaths in
VATS, 1 in control
Koizumi
7 2003 17 VATS
15 Open
Complications, survival Trend favors VATS Pts age 80
Demmy
9 2004 20 VATS
38 Open
Discharge
independence, LOS
Shorter LOS, less pain,
fewer transfers to care
facilities
Groups well matched
Kawai
10 2005 10 VATS
11 Open
Nocturnal hypoxemia
POD 3 and 14
Less hypoxemia at POD 14
with VATS
Open were 2 cm, VATS
were  2c m
Nagahiro
11 2001 13 VATS
9 Open
PFTs, pain, cytokines Less pain, lower IL-6 in
VATS
Open were T2, VATS were T1
Nakata
12 2000 10 VATS
11 Open
PFTs, early and late PFTs better for VATS pod
7, no change at 1 year
Selection of controls ill-
defined, spreading used
Yim
13 2000 18 VATS
18 Open
Cytokines, analgesic
requirement
IL-6, IL-8, IL-10 lower and
less IV narcotic in VATS
Controls were initially
attempted VATS
Kaseda
14 2000 44 VATS
77 Open
PFTs 3 months post-
op, survival
PFT changes and Stage I
survival better for VATS
Historical controls not well
defined
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the VATS cases were T1.10
Case Series
Numerous case series have been published, many of
which have been updated reflecting the ongoing experi-
ence of the authors, follow-up of patients, and modifica-
tions in technique. The series published in English with
more than 100 patients are reviewed in Table 3.15–24
Roviaro and colleagues1 from Milan have been publishing
on their experience with VATS for major lung resections
since 1993. Their most recent update looked at their 11-
year experience with 344 patients (278 with NSCLC, 6
metastases, 68 benign) that went to surgery for VATS
major resection. In patients with lung cancer, their indi-
cations were clinical stage I with peripheral tumors 3c m
in diameter.15 Their technique does not use rib-spreading
and involves 3 incisions to 4 incisions with the largest
being 5cm for withdrawal of the specimen.
Two recent case series have been published from different
centers in Japan.16,17 Iwasaki and colleagues16 published
their experience with 140 procedures (100 lobes, 40 seg-
ments). Their technique did not involve rib-spreading,
and their indications were clinical stage I disease with
peripheral tumors 3 cm. They reported a 5-year survival
of 77.3% for the VATS patients with 80.9% for stage I and
70.3% for stage II tumors.
The other Japanese case series involved 106 patients, 95 of
whom had a VATS procedure and the other 11 of whom
were converted to thoracotomy (10% conversion rate).17
Their main indication was clinical stage I. Tumor size was
not a criterion. Their technique involved the use of a
mini-thoracotomy and rib-spreading. They reported a
3-year survival of 93%, but only included the 82 patients
Table 3.
Case Series of VATS Major Lung Resections
Study Patients
(ITT)
Technique Survival LOS Days Comment
Roviaro
15 2004 259 (344) No spreading 5y 68.9 5 78 (23%) conversions, 2
deaths
Iwasaki
16 2004 140 No spreading 5y 77.3%
I 80.9%
II 70.3%
NR 100 lobes, 40 segments
Ohtsuka
17 2004 95 (106) Spreading 3y 93% 7.6 Survival in only 82
patients, 1 death, 10%
conversion
Walker
18 2003 158 (178) No spreading 5y
I 77.9%
II 51.4%
6 1.8% 30d mortality, 11%
conversion
Gharagozloo
23 2003 179 Simultaneous
stapling, no
spreading
5y 83% 4.1 1 death
Solaini
19 2001 112 (125) No spreading 3y 85%
I9 0
6.2 Survival in 86 patients
with NSCLC, 10%
conversion
Lewis
22 1999 250 Simultaneous
stapling, no
spreading
3y 83% 2.8 About half of patients
were stage II
Yim
20 1998 214 (266) Spreading 2y 93% NR 1.8% 30d mortality, 19%
conversion
McKenna
21 2006 1100 No spreading 5y
I80%
II60%
3 med 4.78
mean
0.8% mortality, 2.5%
conversion, port site
recurrence-0.6%
Onaitis
24 500 No spreading 2y 80% 3 1% mortality, 1.6%
conversion
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months. Yim and colleagues20 from Hong Kong published
their series of 266 patients with tumors 5 cm for whom
they attempted VATS resections. They converted to tho-
racotomy 19% of the time, and completed 214 VATS major
lung resections. A rib-spreader was used. They reported a
22% incidence of nonfatal complications, 1 postoperative
death, and 93% of patients alive at 2 years.
In the largest series of VATS major lung resections, McK-
enna and colleagues21 reported on their experience of
1100 patients for whom they performed 1072 procedures
with a conversion rate of 2.5%. There were no intraoper-
ative deaths, and their mortality was only 0.8%. The com-
plication rate was 15.3% with the most common compli-
cations being prolonged air leak and atrial fibrillation.
Kaplan-Meier survival curves are presented, and extrapo-
lation shows 5-year survivals for stage I and II cancers of
approximately 80% and 60%, respectively. The incidence
of port-site recurrence was 0.6%.
Finally, 2 independent series22,23 using forms of simulta-
neous stapling have been published. This technique in-
volves no rib-spreading, but variations on stapling the
bronchus and vascular structures together without formal
dissection. Lewis22 reported a complication rate of 11.2%
and 3-year survival of 83%. Of note, almost half of the
patients were stage II. Gharagozloo23 reported on 179
patients with a 5-year survival of 83%. They performed 29
right upper and middle bilobectomies (16%) in the series.
This high number was performed as a conscious decision
after some early recurrences in the N1 nodes between
upper and middle lobes.
DISCUSSION
As detailed above, the bulk of the evidence is in the form
of case series and case-control studies with few published
RCTs. Synthesizing the data, some conclusions can be
drawn:
• VATS lobectomy can be performed safely with equiv-
alent mortality and complication rates to that of open
lobectomy. This is based on the results of 2 small RCTs
and a number of case-control trials and case se-
ries.3,4,7,8,14–27
• The survival of patients with stage I lung cancer follow-
ing VATS lobectomy is equivalent to that of patients
having open surgery. This is based on one small RCT,
case-control studies, and the case series.4,7,14–27
• Patients experience less pain with VATS based on case-
control studies.1,8,9,25,26
• Length of hospital stay is similar to that of open proce-
dures. One RCT showed no difference, and 3 case-
control studies suggested it was shorter with
VATS.3,8,9,26
Because the published evidence is thin, no definite rec-
ommendations can be made. The reality of the situation is
that many surgeons are performing the procedure and
many patients are requesting it. The data support that
VATS lobectomy can be done safely and that the survival
of early-stage patients is equivalent to that of thoracot-
omy. In terms of the postoperative course, although the
data are mixed, there seems to be a suggestion that VATS
patients have less pain and shorter hospital stays.
Differences in indications, technique, and extents of lymph
node dissection make comparing across studies difficult. If
one can perform the same operation in terms of anatomic
dissection and lymph node removal as done through thora-
cotomy, then it would seem reasonable to offer a VATS
lobectomy. The therapeutic role of lymph node dissection
will remain unanswered for the time being until the survival
results of the recently completely American College of Sur-
geons Oncology Group (ACOSOG) Z0030 study, comparing
mediastinal lymph node dissection to sampling, are matur-
ing. In the interim, few thoracic surgical oncologists would
dispute the importance of lymph node dissection, particu-
larly in view of the evidence that it does not increase mor-
bidity or mortality and it aids in the selection of patients for
adjuvant chemotherapy in the presence of lymph node in-
volvement.28 With that in mind, it would seem the real
question of whether or not to perform VATS lobectomies
hinges on the completeness of the lymph node dissection.
Few studies have been performed to assess the adequacy
of lymph node dissection in VATS lobectomy. Sagawa and
colleagues29 conducted an interesting study by perform-
ing a VATS lobectomy and mediastinal lymph node dis-
section (with rib-spreading) followed by a conversion to
thoracotomy at the same operation to assess the residual
lymphatic tissue that remained unresected. In 29 patients,
the mass of lymphatic tissue “missed” by VATS lobectomy
was 3% of the amount resected, which they judged to be
an adequate result. In a more conventional retrospective
analysis, Watanabe et al27 compared 191 VATS lobectomy
patients with 159 thoracotomy patients. They demon-
strated that the number of nodes dissected was similar in
both groups. Shiraishi and colleagues25 also noted in their
small case-control study that the number of mediastinal
lymph nodes dissected was similar in VATS and open
groups. It should be noted that Japanese surgeons are
generally regarded as being particularly aggressive in their
lymph node dissections. This importance on lymphade-
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ing this issue in VATS lobectomy are from Japan.
Our practice has been to offer VATS lobectomy using no
rib-spreading to patients with clinical stage I cancers with
peripheral tumors 3 cm in diameter. Contraindications
include the use of preoperative chemotherapy or radio-
therapy. Lobectomy remains the standard of care for all
early lung cancers. As such, the use of simultaneous sta-
pling techniques is probably not warranted particularly in
light of the increased number of bilobectomies performed
by one center due to the inadequacy of their lymph node
removals. It would seem that this is not the same opera-
tion as an open lobectomy.
CONCLUSION
There is certainly a need for further study. A large multi-
center randomized trial comparing open lobectomy to
VATS lobectomy would be ideal. However, the myriad of
techniques used by different surgeons would make the
standardization of the VATS arm difficult or impossible.
Quality of life studies with validated instruments need to
be performed to ascertain the impact of VATS. Another
interesting avenue of investigation that has been em-
barked on but requires further study is the use of VATS in
higher risk groups to see whether they fare better. Also,
with the recent shift in clinical practice to adjuvant che-
motherapy for more and more of our patients, there may
be some additional benefit to VATS lobectomy if patients
are better able to tolerate chemotherapy postoperatively.
This should also be a subject of future studies.
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